Sitagliptin (sitagliptin)

Sitagliptin is approved for: US (FDA): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, as monotherapy and in combination therapy.; Limitation of use: should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.; Limitation of use: has not been studied in patients with a history of pancreatitis.. It is a sitagliptin (Dipeptidyl peptidase-4), originally marketed as Januvia (捷诺维) by Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc..

The FDA listed sitagliptin phosphate tablets from Watson Laboratories Inc. (ANDA 202327) in its 2025 First Generic Drug Approvals with an approval date of 12/30/2025 against Januvia, establishing an ANDA-level bioequivalence route. Zituvio (Zydus Lifesciences) is a separately FDA-approved sitagliptin product (approved 18 Oct 2023) rather than a substituted ANDA generic. Indian and Bangladeshi products (Cipla Sitacip, Sun Istavel, Beximco Glipita, Incepta Sitagil, Sun Bangladesh Glucodip) are national-approval generics based on national bioequivalence requirements. Manufacturers supplying sitagliptin generic versions include ACI Limited, ACME Laboratories Ltd, Beximco Pharmaceuticals Ltd, Cipla Ltd, Drug International Ltd, Eskayef Pharmaceuticals Ltd, Incepta Pharmaceuticals Ltd, Square Pharmaceuticals PLC. Brands registered in Bangladesh include D-Glip, Glipita, Glucodip, Incrit, Janvia, Radiglip.

Standard dosing for sitagliptin: Adults: 100 mg once daily, with or without food, as monotherapy or added to metformin, a sulfonylurea, a thiazolidinedione or insulin. When added to an insulin secretagogue (e.g. a sulfonylurea) or to insulin, a lower dose of the secretagogue or insulin may be needed to reduce the risk of hypoglycaemia. Dose adjustments: Renal (per the US label): mild impairment CrCl >=50 mL/min - no adjustment, 100 mg once daily; moderate impairment CrCl >=30 to <50 mL/min - 50 mg once daily; severe impairment CrCl <30 mL/min or end-stage renal disease including dialysis - 25 mg once daily. Renal function should be assessed before starting and periodically afterwards because postmarketing acute renal failure has been reported. Hepatic: the US label gives no specific hepatic dose adjustment; section 8 of the label considers hepatic impairment separately.

Sitagliptin (Dipeptidyl peptidase-4 (DPP-4) inhibitor, oral antidiabetic. ATC A10BH01., originally Januvia (捷诺维) by Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.) Sitagliptin slows the enzyme DPP-4 that normally breaks down the gut hormones GLP-1 and GIP. With those hormones lasting longer, the pancreas releases more insulin after a meal and produces less glucagon, so blood sugar falls. Because the effect is glucose-dependent, it rarely causes hypoglycaemia on its own and does not cause weight gain. Adults: 100 mg once daily, with or without food, as monotherapy or added to metformin, a sulfonylurea, a thiazolidinedione or insulin. When added to an insulin secretagogue (e.g. a sulfonylurea) or to insulin, a lower dose of the secretagogue or insulin may be needed to reduce the risk of hypoglycaemia.

Sitagliptin (Dipeptidyl peptidase-4 (DPP-4) inhibitor, oral antidiabetic. ATC A10BH01., originally Januvia (捷诺维) by Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.) Sitagliptin slows the enzyme DPP-4 that normally breaks down the gut hormones GLP-1 and GIP. With those hormones lasting longer, the pancreas releases more insulin after a meal and produces less glucagon, so blood sugar falls. Because the effect is glucose-dependent, it rarely causes hypoglycaemia on its own and does not cause weight gain. Adults: 100 mg once daily, with or without food, as monotherapy or added to metformin, a sulfonylurea, a thiazolidinedione or insulin. When added to an insulin secretagogue (e.g. a sulfonylurea) or to insulin, a lower dose of the secretagogue or insulin may be needed to reduce the risk of hypoglycaemia.

The FDA listed sitagliptin phosphate tablets from Watson Laboratories Inc. (ANDA 202327) in its 2025 First Generic Drug Approvals with an approval date of 12/30/2025 against Januvia, establishing an ANDA-level bioequivalence route. Zituvio (Zydus Lifesciences) is a separately FDA-approved sitagliptin product (approved 18 Oct 2023) rather than a substituted ANDA generic. Indian and Bangladeshi products (Cipla Sitacip, Sun Istavel, Beximco Glipita, Incepta Sitagil, Sun Bangladesh Glucodip) are national-approval generics based on national bioequivalence requirements. Manufacturers supplying sitagliptin generic versions include ACI Limited, ACME Laboratories Ltd, Beximco Pharmaceuticals Ltd, Cipla Ltd, Drug International Ltd, Eskayef Pharmaceuticals Ltd, Incepta Pharmaceuticals Ltd, Square Pharmaceuticals PLC. Brands registered in Bangladesh include D-Glip, Glipita, Glucodip, Incrit, Janvia, Radiglip.

Bangladesh benchmark: 20 manufacturers sell generic sitagliptin 50 mg; unit prices range from BDT 13 (US$0.11) to BDT 18 (US$0.15), i.e. about US$3.17–US$4.41 per 30 units. Cheapest listed brand: D-Glip (Desh Pharmaceuticals Ltd.) at BDT 13 per unit. Prices move with pack size, pharmacy and the exchange rate — confirm current stock and price with a licensed importer before ordering.

Sitagliptin (Dipeptidyl peptidase-4 (DPP-4) inhibitor, oral antidiabetic. ATC A10BH01., originally Januvia (捷诺维) by Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.) Sitagliptin slows the enzyme DPP-4 that normally breaks down the gut hormones GLP-1 and GIP. With those hormones lasting longer, the pancreas releases more insulin after a meal and produces less glucagon, so blood sugar falls. Because the effect is glucose-dependent, it rarely causes hypoglycaemia on its own and does not cause weight gain. Adults: 100 mg once daily, with or without food, as monotherapy or added to metformin, a sulfonylurea, a thiazolidinedione or insulin. When added to an insulin secretagogue (e.g. a sulfonylurea) or to insulin, a lower dose of the secretagogue or insulin may be needed to reduce the risk of hypoglycaemia.

Renal (per the US label): mild impairment CrCl >=50 mL/min - no adjustment, 100 mg once daily; moderate impairment CrCl >=30 to <50 mL/min - 50 mg once daily; severe impairment CrCl <30 mL/min or end-stage renal disease including dialysis - 25 mg once daily. Renal function should be assessed before starting and periodically afterwards because postmarketing acute renal failure has been reported. Hepatic: the US label gives no specific hepatic dose adjustment; section 8 of the label considers hepatic impairment separately. Drug interactions matter most with strong CYP3A4 inducers/inhibitors and with other medicines that prolong the QT interval or suppress the immune system. Always show your full medication list to the prescribing physician.

Storage: Store at 20-25 C (68-77 F); excursions permitted to 15-30 C (59-86 F) - USP Controlled Room Temperature. Keep the product in its original packaging and check the expiry date printed on the pack.